Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | The significant impact of PSMA-PET on prostate cancer staging and management

Jeremie Calais • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Prostate Cancer

Jeremie Calais, MD, University of California, Los Angeles, CA, talks on the clinical significance PSMA-PET in terms of both the staging and management of prostate cancer in various settings. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Jeremie Calais

2:10
Exploring the new frontier: radionuclide therapy in metastatic prostate cancer
Jeremie Calais • 3 Jun 2023
4:16
PSMA PET guided salvage RT among patients with prostate cancer in the post-prostatectomy setting
Jeremie Calais • 3 Jun 2023
2:10
Integrating radioligand therapy for prostate cancer in US clinical practice
Jeremie Calais • 4 Jun 2023
2:56
PSMA PET ratio predicts response to [177Lu]PSMA radioligand therapy: a multicenter study
Jeremie Calais • 4 Jun 2023

Related Videos

0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
0:38
Emerging combinatory immunotherapies show promise for mCRPC
Hannah McManus • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals